Oesophageal, gastric and intestinal inflammatory disease

Our group leads a CIBERehd (Biomedical Research Network for Liver and Digestive Diseases) research team focused on the understanding and management of Helicobacter pylori infection and Inflammatory Bowel Disease (IBD). Different projects have been developed in collaboration with various departments at Hospital de La Princesa, research institutes and universities, and a network of digestive departments across Spain.

In 2014, the group continued this approach in European and international contexts:

  • The group coordinates the European registry on the management of H.pylori infection in which 300 gastroenterologists from 30 European countries participate, making it the largest study of any infectious agent.
  • United European Gastroentorology has awarded this team a long-term educational project aimed at improving knowledge and implementation of the European Consensus on pylori infection in nine European countries.

Our group’s strategic plan for the next five years will be framed under three key elements: Collaboration, Internationalisation and transfer “from the laboratory to the patient”.

The European Registry has made a call for collaboration that will increase our national and international collaboration network. We have promoted a stable strategic IBD consortium between the Spanish IBD Society (GETECCU, Grupo Español de Trabajo en Enfermedad de Crohn y Colitis ulcerosa), the Centro de Investigación Biomédica en Red (CIBER, Centre for Biomedical Research Network) and the Red Española de Unidades de Ensayos Clínicos (Spanish Network of Clinical Trial Units).

This agreement has created a central scientific unit, supervised by our team, to coordinate, promote and monitor clinical, researcher-driven IBD research. In addition, our group has created and is leading the consortium formed between the Asociación Española de Gastroenterología (AEG, Spanish Gastroenterology Association) and the REDCap platform that will provide a free and powerful online system for data capture, surveys and coordination of multi-centre projects.

The group has been selected by the European Helicobacter Study Group to coordinate an international project on microbiota alterations related to H. pylori infection and treatment to eradicate it.

With the idea of increasing our Translational Research, we have reached agreements with different basic research groups (Departments of Microbiology, Molecular Biology, etc.) for long-term synergistic collaborations, and we have taken on a new researcher with accredited experience in translational science in digestive immune response, genetics and microbiota, to coordinate our basic research.

[/fusion_accordion]
Team members

Group leader:

Javier Pérez Gisbert

Hospital Universitario La Princesa

  Other team members:

  • Diana Acosta Rubio. Fundación para la Investigación Biomédica Hospital Universitario de La Princesa.
  • Montserrat Baldán Martín. CIBER.
  • María José Beceiro Pedreño. Hospital Universitario La Princesa.
  • Yanire Brenes Ruiz. Fundación para la Investigación Biomédica Hospital Universitario de La Princesa.
  • María José Casanova González. Hospital Universitario La Princesa.
  • María Chaparro Sánchez. Hospital Universitario La Princesa.
  • Almudena Duran Vegue. CIBER.
  • María García Donday. Fundación para la Investigación Biomédica Hospital Universitario de La Princesa.
  • Ana Isabel Garre Vázquez. Fundación para la Investigación Biomédica Hospital Universitario de La Princesa.
  • Sandra Hermida Vázquez. Fundación para la Investigación Biomédica Hospital Universitario de La Princesa.
  • Macarena Orejudo del Río. CIBER.
  • Laura María Palomino Pérez. Hospital Infantil Universitario Niño Jesús.
  • Pablo Parra Pineda. Fundación para la Investigación Biomédica Hospital Universitario de La Princesa.
  • Cristina Ramírez Belinchón. Fundación para la Investigación Biomédica Hospital Universitario de La Princesa.
  • Cristina Rubin de Célix Vargas. Hospital Universitario La Princesa.
  • Irene Soleto Fernández. Fundación para la Investigación Biomédica Hospital Universitario de La Princesa.
  • Marta Velasco Rodríguez-Belvis. Hospital Infantil Universitario Niño Jesús.

Bernardo Ordiz, David. Efecto de los péptidos inmunomoduladores secretados por la microbiota intestinal sobre las células dendríticas de la mucosa en los pacientes con Colitis Ulcerosa. GETECCU-MSD. 2017-2018.

Chaparro Sánchez, María. Proteomic characterization of extracellular vesicles in inflammatory bowel diseases: a novel proteomic approach for biomarker discovery. GETECCU-Faes Farma. 2017-2018.

Chaparro Sánchez, María. Estudio prospectivo y multicéntrico sobre la epidemiología y características “ómicas” de la enfermedad inflamatoria intestinal de reciente diagnóstico en España. PI16/01296. ISCIII. 2017-2019.

Evaluar la incidencia de la enfermedad inflamatoria intestinal.

This grant is funded by the 2013-2016 Spanish Science, Technology and Innovation Research Plan and the ISCIII – Subdirectorate General for Evaluation and Promotion of Research – and co-financed by the European Regional Development Fund, Operational Programme Smart Growth 2014-2020 according to Regulation (EU) no. 1303/2013.

logo-feder

Pérez Gisbert, Javier. Immunoregulatory molecules as biomarkers predicting response to biological therapies and disease severity in immune-mediated inflammatory disorders. BIOMID PROJECT. PIE13/00041. Coordinated project. ISCIII. 2014-2016.

logo-federPérez Gisbert, Javier. Cátedra de patrocinio de docencia e investigación en enfermedad inflamatoria intestinal ABBVIE – UAM. Departamento de Medicina de la Universidad Autónoma de Madrid. 2014-2016.

Pérez Gisbert, Javier. OPTICARE: Optimal h. Pylori management in primary care. United European Gastroenterology. 2013-2015.

Chaparro Sánchez, María. Predicción de respuesta a corto y largo plazo al tratamiento con fármacos anti-TNF en pacientes con enfermedad de Crohn. Estudio PREDICROHN. ISCIII. PI12/02557. 2013-2015.

Bernardo Ordiz, David. Compartimentalización de las células dendríticas intestinales humanas en enfermedad de Crohn. SAF2014-56642-JIN. MINECO. 2015-2017.

Pérez Gisbert, Javier. Suspensión del tratamiento anti-TNF en pacientes con enfermedad inflamatoria intestinal: ensayo clínico multicéntrico, prospectivo y aleatorizado. PI15/00560. ISCIII. 2016-2018.

Chaparro Sánchez, María. Los exosomas séricos en la enfermedad de Crohn: caracterización molecular y significado clínico. Beca Gonzalo Miño de la Fundación Española de Gastroenterología. 2015-2017.

Santander Vaquero, Cecilio. Esofagitis eosinofílica: estudios en biopsia esofágica y sangre periférica para la identificación de biomarcadores de la enfermedad y de la respuesta al tratamiento. PI17/00008. ISCIII. 2018-2020.

Analizar los cambios en la expresión génica y de proteínas en biopsias esofágicas de pacientes adultos con esofagitis eosinofílica.

This grant is funded by the 2013-2016 Spanish Science, Technology and Innovation Research Plan and the ISCIII – Subdirectorate General for Evaluation and Promotion of Research – and co-financed by the European Regional Development Fund, Operational Programme Smart Growth 2014-2020 according to Regulation (EU) no. 1303/2013.

logo-feder

Chaparro Sánchez, María. Proteomic characterization of extracellular vesicles in inflammatory bowel diseases: a novel proteomic approach for biomarker discovery. European Crohn’s and Colitis Organisation. 2018.

Pérez Gisbert, Javier. Identificación de biomarcadores de respuesta al tratamiento con fármacos biológicos en la enfermedad inflamatoria intestinal mediante abordaje proteómico y de citometría de masas. PI18/00622. ISCIII. 2019-2021.

Uso de técnicas másivas de citometría de masas y proteómica para la identificación de biomarcadores para el mejor tratamiento de la enfermedad inflamatoria intestinal (EII).

This grant is funded by the 2017-2020 Spanish Science, Technology and Innovation Research Plan and the ISCIII – Subdirectorate General for Evaluation and Promotion of Research – and co-financed by the European Regional Development Fund, Operational Programme Smart Growth 2014-2020 according to Regulation (EU) no. 1303/2013.

Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012. 61: 646-664. FI: 10.732(Q1). PMID: 22491499. DOI: 10.1136/gutjnl-2012-302084.

Gisbert JP, Calvet X, Cosme A, Almela P, Feu F, Bory F, Santolaria S, Aznárez R, Castro M, Fernández N, García-Grávalos R, Benages A, Cañete N, Montoro M, Borda F, Pérez-Aisa A, Piqué JM. Long-Term Follow-Up of 1,000 Patients Cured of Helicobacter pylori Infection Following an Episode of Peptic Ulcer Bleeding. Am J Gastroenterol 2012. 107: 1197-1204. FI: 7.553(Q1). PMID: 22613904. DOI: 10.1038/ajg.2012.132.

Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. LANCET 2012. 380: 1909-1915. FI: 39.060(Q1). PMID: 23063316. DOI: 10.1016/S0140-6736(12)61084-8.

Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance. Gastroenterology 2013. 145: 121-0. FI: 13.926(Q1). PMID: 23562754. DOI: 10.1053/j.gastro.2013.03.050.

McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014. 63: 244-249. FI: 14.660(Q1). PMID: 23665990. DOI: 10.1136/gutjnl-2013-304820.